Annual FCF
$61.86 M
-$54.16 M-46.68%
31 December 2023
Summary:
Catalyst Pharmaceuticals annual free cash flow is currently $61.86 million, with the most recent change of -$54.16 million (-46.68%) on 31 December 2023. During the last 3 years, it has risen by +$16.83 million (+37.39%). CPRX annual FCF is now -46.68% below its all-time high of $116.02 million, reached on 31 December 2022.CPRX Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
$72.61 M
+$8.49 M+13.24%
30 September 2024
Summary:
Catalyst Pharmaceuticals quarterly free cash flow is currently $72.61 million, with the most recent change of +$8.49 million (+13.24%) on 30 September 2024. Over the past year, it has increased by +$106.84 million (+312.17%). CPRX quarterly FCF is now at all-time high.CPRX Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
$221.79 M
+$106.84 M+92.94%
30 September 2024
Summary:
Catalyst Pharmaceuticals TTM free cash flow is currently $221.79 million, with the most recent change of +$106.84 million (+92.94%) on 30 September 2024. Over the past year, it has increased by +$173.19 million (+356.34%). CPRX TTM FCF is now at all-time high.CPRX TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CPRX Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -46.7% | +312.2% | +356.3% |
| 3 y3 years | +37.4% | +235.6% | +316.0% |
| 5 y5 years | +335.7% | +346.5% | +1496.5% |
CPRX Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -46.7% | +37.4% | at high | +312.2% | at high | +356.3% |
| 5 y | 5 years | -46.7% | +335.7% | at high | +312.2% | at high | +1496.5% |
| alltime | all time | -46.7% | +335.7% | at high | +312.2% | at high | +887.0% |
Catalyst Pharmaceuticals Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $72.61 M(+13.2%) | $221.79 M(+92.9%) |
| June 2024 | - | $64.13 M(+102.1%) | $114.96 M(+40.9%) |
| Mar 2024 | - | $31.73 M(-40.5%) | $81.59 M(+31.9%) |
| Dec 2023 | $61.86 M(-46.7%) | $53.33 M(-255.8%) | $61.86 M(+27.3%) |
| Sept 2023 | - | -$34.22 M(-211.3%) | $48.60 M(-60.8%) |
| June 2023 | - | $30.75 M(+156.4%) | $124.13 M(+3.8%) |
| Mar 2023 | - | $12.00 M(-70.1%) | $119.54 M(+3.0%) |
| Dec 2022 | $116.02 M(+95.5%) | $40.08 M(-3.0%) | $116.02 M(+22.0%) |
| Sept 2022 | - | $41.30 M(+57.9%) | $95.08 M(+26.1%) |
| June 2022 | - | $26.16 M(+208.6%) | $75.41 M(+16.2%) |
| Mar 2022 | - | $8.48 M(-55.7%) | $64.93 M(+9.4%) |
| Dec 2021 | $59.35 M(+31.8%) | $19.14 M(-11.6%) | $59.35 M(+11.3%) |
| Sept 2021 | - | $21.64 M(+38.1%) | $53.32 M(+23.7%) |
| June 2021 | - | $15.67 M(+439.9%) | $43.12 M(+5.9%) |
| Mar 2021 | - | $2.90 M(-77.8%) | $40.71 M(-9.6%) |
| Dec 2020 | $45.02 M(+30.2%) | $13.11 M(+14.6%) | $45.02 M(+1.8%) |
| Sept 2020 | - | $11.44 M(-13.8%) | $44.21 M(-9.8%) |
| June 2020 | - | $13.27 M(+83.9%) | $49.03 M(-1.6%) |
| Mar 2020 | - | $7.21 M(-41.3%) | $49.83 M(+44.0%) |
| Dec 2019 | $34.59 M(-231.8%) | $12.29 M(-24.4%) | $34.59 M(+149.0%) |
| Sept 2019 | - | $16.26 M(+15.7%) | $13.89 M(-248.6%) |
| June 2019 | - | $14.06 M(-275.3%) | -$9.35 M(-66.8%) |
| Mar 2019 | - | -$8.02 M(-4.6%) | -$28.18 M(+7.4%) |
| Dec 2018 | -$26.24 M(+90.9%) | -$8.41 M(+20.5%) | -$26.24 M(+20.0%) |
| Sept 2018 | - | -$6.98 M(+46.1%) | -$21.86 M(+24.8%) |
| June 2018 | - | -$4.77 M(-21.5%) | -$17.52 M(+9.9%) |
| Mar 2018 | - | -$6.08 M(+50.9%) | -$15.95 M(+16.0%) |
| Dec 2017 | -$13.74 M(-23.9%) | -$4.03 M(+53.1%) | -$13.74 M(-2.8%) |
| Sept 2017 | - | -$2.63 M(-17.8%) | -$14.13 M(-4.4%) |
| June 2017 | - | -$3.20 M(-17.5%) | -$14.78 M(-7.7%) |
| Mar 2017 | - | -$3.88 M(-12.2%) | -$16.01 M(-11.4%) |
| Dec 2016 | -$18.06 M(+0.1%) | -$4.42 M(+34.8%) | -$18.06 M(-1.2%) |
| Sept 2016 | - | -$3.28 M(-26.0%) | -$18.27 M(-10.2%) |
| June 2016 | - | -$4.43 M(-25.3%) | -$20.35 M(+0.9%) |
| Mar 2016 | - | -$5.93 M(+28.0%) | -$20.17 M(+11.8%) |
| Dec 2015 | -$18.04 M | -$4.63 M(-13.6%) | -$18.04 M(+3.7%) |
| Sept 2015 | - | -$5.36 M(+26.2%) | -$17.40 M(+11.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2015 | - | -$4.25 M(+11.7%) | -$15.61 M(+8.7%) |
| Mar 2015 | - | -$3.80 M(-4.8%) | -$14.36 M(+10.5%) |
| Dec 2014 | -$13.00 M(+31.5%) | -$3.99 M(+12.0%) | -$13.00 M(-1.0%) |
| Sept 2014 | - | -$3.57 M(+19.0%) | -$13.14 M(+16.7%) |
| June 2014 | - | -$3.00 M(+22.7%) | -$11.25 M(+11.8%) |
| Mar 2014 | - | -$2.44 M(-40.9%) | -$10.07 M(+1.9%) |
| Dec 2013 | -$9.89 M(+90.4%) | -$4.13 M(+145.3%) | -$9.89 M(+33.7%) |
| Sept 2013 | - | -$1.68 M(-7.1%) | -$7.39 M(+8.6%) |
| June 2013 | - | -$1.81 M(-19.8%) | -$6.81 M(+10.8%) |
| Mar 2013 | - | -$2.26 M(+37.8%) | -$6.15 M(+18.3%) |
| Dec 2012 | -$5.19 M(+4.1%) | -$1.64 M(+48.9%) | -$5.19 M(+4.0%) |
| Sept 2012 | - | -$1.10 M(-4.0%) | -$4.99 M(-2.9%) |
| June 2012 | - | -$1.15 M(-12.2%) | -$5.15 M(-5.8%) |
| Mar 2012 | - | -$1.31 M(-9.3%) | -$5.46 M(+9.5%) |
| Dec 2011 | -$4.99 M(+32.7%) | -$1.44 M(+15.0%) | -$4.99 M(+15.5%) |
| Sept 2011 | - | -$1.25 M(-14.5%) | -$4.32 M(+11.2%) |
| June 2011 | - | -$1.46 M(+76.3%) | -$3.88 M(+8.8%) |
| Mar 2011 | - | -$831.10 K(+8.0%) | -$3.57 M(-5.1%) |
| Dec 2010 | -$3.76 M(-51.1%) | -$769.20 K(-5.9%) | -$3.76 M(-1.6%) |
| Sept 2010 | - | -$817.30 K(-28.9%) | -$3.82 M(-12.3%) |
| June 2010 | - | -$1.15 M(+12.5%) | -$4.35 M(-25.8%) |
| Mar 2010 | - | -$1.02 M(+23.2%) | -$5.87 M(-23.6%) |
| Dec 2009 | -$7.69 M(-7.0%) | -$828.90 K(-38.7%) | -$7.68 M(-21.2%) |
| Sept 2009 | - | -$1.35 M(-49.2%) | -$9.75 M(-10.7%) |
| June 2009 | - | -$2.66 M(-6.1%) | -$10.92 M(+10.6%) |
| Mar 2009 | - | -$2.84 M(-2.2%) | -$9.87 M(+19.5%) |
| Dec 2008 | -$8.26 M(+84.0%) | -$2.90 M(+15.1%) | -$8.26 M(+31.1%) |
| Sept 2008 | - | -$2.52 M(+56.0%) | -$6.30 M(+40.2%) |
| June 2008 | - | -$1.62 M(+31.8%) | -$4.50 M(+3.5%) |
| Mar 2008 | - | -$1.23 M(+30.0%) | -$4.35 M(-3.2%) |
| Dec 2007 | -$4.49 M(+274.4%) | -$942.30 K(+32.0%) | -$4.49 M(+26.6%) |
| Sept 2007 | - | -$714.00 K(-51.3%) | -$3.55 M(+25.2%) |
| June 2007 | - | -$1.46 M(+6.9%) | -$2.83 M(+106.9%) |
| Mar 2007 | - | -$1.37 M | -$1.37 M |
| Dec 2006 | -$1.20 M(+161.2%) | - | - |
| Dec 2005 | -$459.30 K(+97.6%) | - | - |
| Dec 2004 | -$232.40 K | - | - |
FAQ
- What is Catalyst Pharmaceuticals annual free cash flow?
- What is the all time high annual FCF for Catalyst Pharmaceuticals?
- What is Catalyst Pharmaceuticals annual FCF year-on-year change?
- What is Catalyst Pharmaceuticals quarterly free cash flow?
- What is the all time high quarterly FCF for Catalyst Pharmaceuticals?
- What is Catalyst Pharmaceuticals quarterly FCF year-on-year change?
- What is Catalyst Pharmaceuticals TTM free cash flow?
- What is the all time high TTM FCF for Catalyst Pharmaceuticals?
- What is Catalyst Pharmaceuticals TTM FCF year-on-year change?
What is Catalyst Pharmaceuticals annual free cash flow?
The current annual FCF of CPRX is $61.86 M
What is the all time high annual FCF for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals all-time high annual free cash flow is $116.02 M
What is Catalyst Pharmaceuticals annual FCF year-on-year change?
Over the past year, CPRX annual free cash flow has changed by -$54.16 M (-46.68%)
What is Catalyst Pharmaceuticals quarterly free cash flow?
The current quarterly FCF of CPRX is $72.61 M
What is the all time high quarterly FCF for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals all-time high quarterly free cash flow is $72.61 M
What is Catalyst Pharmaceuticals quarterly FCF year-on-year change?
Over the past year, CPRX quarterly free cash flow has changed by +$106.84 M (+312.17%)
What is Catalyst Pharmaceuticals TTM free cash flow?
The current TTM FCF of CPRX is $221.79 M
What is the all time high TTM FCF for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals all-time high TTM free cash flow is $221.79 M
What is Catalyst Pharmaceuticals TTM FCF year-on-year change?
Over the past year, CPRX TTM free cash flow has changed by +$173.19 M (+356.34%)